Jinhe Biotechnology Co Ltd (002688) — Working Capital to Net Assets Ratio
Jinhe Biotechnology Co Ltd (002688) has a Working Capital to Net Assets ratio of -4.7% as of September 2025. Working capital of CN¥-122.22 Million (current assets of CN¥1.92 Billion minus current liabilities of CN¥2.04 Billion) is measured against net assets of CN¥2.60 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how many days can Jinhe Biotechnology Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Jinhe Biotechnology Co Ltd Working Capital to Net Assets (2008–2024)
This chart shows how Jinhe Biotechnology Co Ltd's Working Capital to Net Assets ratio has evolved across 17 annual periods from 2008 to 2024. As of September 2025, the ratio stands at -4.7%, reflecting working capital of CN¥-122.22 Million against net assets of CN¥2.60 Billion CNY. For the complete balance sheet picture, see Jinhe Biotechnology Co Ltd balance sheet assets.
Annual Working Capital to Net Assets for Jinhe Biotechnology Co Ltd (2008–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Jinhe Biotechnology Co Ltd from 2008 to 2024, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Jinhe Biotechnology Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 6.4% | CN¥159.49 Million | CN¥2.50 Billion | CN¥2.02 Billion | CN¥1.86 Billion | ▲ +15.0 pp |
| 2023 | -8.7% | CN¥-217.74 Million | CN¥2.52 Billion | CN¥2.04 Billion | CN¥2.26 Billion | ▼ -12.0 pp |
| 2022 | 3.4% | CN¥81.88 Million | CN¥2.43 Billion | CN¥1.75 Billion | CN¥1.66 Billion | ▼ -14.7 pp |
| 2021 | 18.0% | CN¥486.27 Million | CN¥2.70 Billion | CN¥1.65 Billion | CN¥1.16 Billion | ▲ +25.6 pp |
| 2020 | -7.6% | CN¥-132.91 Million | CN¥1.75 Billion | CN¥1.24 Billion | CN¥1.37 Billion | ▼ -12.9 pp |
| 2019 | 5.3% | CN¥95.37 Million | CN¥1.81 Billion | CN¥1.24 Billion | CN¥1.15 Billion | ▼ -6.7 pp |
| 2018 | 12.0% | CN¥212.81 Million | CN¥1.78 Billion | CN¥1.32 Billion | CN¥1.10 Billion | ▼ -1.8 pp |
| 2017 | 13.8% | CN¥225.18 Million | CN¥1.64 Billion | CN¥1.08 Billion | CN¥855.12 Million | ▼ -7.5 pp |
| 2016 | 21.2% | CN¥336.15 Million | CN¥1.58 Billion | CN¥865.20 Million | CN¥529.05 Million | ▲ +22.2 pp |
| 2015 | -1.0% | CN¥-10.05 Million | CN¥1.05 Billion | CN¥801.94 Million | CN¥811.99 Million | ▼ -57.3 pp |
| 2014 | 56.4% | CN¥538.86 Million | CN¥956.13 Million | CN¥764.88 Million | CN¥226.02 Million | ▲ +3.6 pp |
| 2013 | 52.8% | CN¥475.13 Million | CN¥900.07 Million | CN¥575.23 Million | CN¥100.10 Million | ▼ -10.6 pp |
| 2012 | 63.4% | CN¥547.54 Million | CN¥863.55 Million | CN¥669.89 Million | CN¥122.36 Million | ▲ +60.5 pp |
| 2011 | 2.9% | CN¥9.79 Million | CN¥334.40 Million | CN¥324.95 Million | CN¥315.16 Million | ▲ +16.2 pp |
| 2010 | -13.3% | CN¥-33.80 Million | CN¥254.83 Million | CN¥272.60 Million | CN¥306.40 Million | ▲ +38.7 pp |
| 2009 | -51.9% | CN¥-101.80 Million | CN¥196.03 Million | CN¥304.87 Million | CN¥406.67 Million | ▲ +16.7 pp |
| 2008 | -68.6% | CN¥-122.05 Million | CN¥177.82 Million | CN¥249.85 Million | CN¥371.90 Million | — |